AxogenAXGN
About: Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
Employees: 428
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
69,267% more call options, than puts
Call options by funds: $4.16M | Put options by funds: $6K
238% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 13
86% more capital invested
Capital invested by funds: $274M [Q2] → $510M (+$236M) [Q3]
25% more funds holding
Funds holding: 125 [Q2] → 156 (+31) [Q3]
20% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 40
3.49% less ownership
Funds ownership: 86.48% [Q2] → 82.99% (-3.49%) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for AXGN.
Financial journalist opinion
Based on 3 articles about AXGN published over the past 30 days
